EP Patent

EP2174935A1 — Linezolid Compositions

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2010-04-14 · 16y expired

What this patent protects

The present invention provides novel pharmaceutical compositions comprising a crystalline form of linezolid referred to herein as Form IV.

USPTO Abstract

The present invention provides novel pharmaceutical compositions comprising a crystalline form of linezolid referred to herein as Form IV.

Drugs covered by this patent

vadadustat (VADADUSTAT)

Patent Metadata

Patent number: EP2174935A1
Jurisdiction: EP
Classification: —
Expires: 2010-04-14
Drug substance claim: No
Drug product claim: No
Assignee: Teva Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.